MCID: RSC001
MIFTS: 61

Rosacea

Categories: Blood diseases, Skin diseases, Smell/Taste diseases

Aliases & Classifications for Rosacea

MalaCards integrated aliases for Rosacea:

Name: Rosacea 12 26 44 45 15 17 74 64
Erythematotelangiectatic Rosacea 26
Papulopustular Rosacea 26
Granulomatous Rosacea 26
Acne, Erythematosa 12
Phymatous Rosacea 26
Ocular Rosacea 26
Acne Roscea 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8881
ICD9CM 36 695.3
MeSH 45 D012393
NCIt 51 C97136
SNOMED-CT 69 1612004
ICD10 34 L71 L71.9
UMLS 74 C0035854

Summaries for Rosacea

MedlinePlus : 44 Rosacea is a long-term disease that affects your skin and sometimes your eyes. It causes redness and pimples. Rosacea is most common in women and people with fair skin. It most often affects middle-aged and older adults. In most cases, rosacea only affects the face. Symptoms can include Frequent redness of the face, or flushing Small, red lines under the skin Acne A swollen nose Thick skin, usually on the forehead, chin, and cheeks Red, dry, itchy eyes and sometimes vision problems No one knows what causes rosacea. You may be more likely to have it if you blush a lot or if rosacea runs in your family. Rosacea is not dangerous. There is no cure, but treatments can help. They include medicines and sometimes surgery. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Rosacea, also known as erythematotelangiectatic rosacea, is related to contact dermatitis and pyoderma, and has symptoms including pruritus and exanthema. An important gene associated with Rosacea is CAMP (Cathelicidin Antimicrobial Peptide), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Ivermectin and Doxycycline have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and testes, and related phenotypes are homeostasis/metabolism and hematopoietic system

Genetics Home Reference : 26 Rosacea is a long-lasting (chronic) skin disease that affects the face, primarily the forehead, nose, cheeks, and chin. The signs and symptoms of rosacea vary, and they may come and go or change over time.

PubMed Health : 64 About rosacea: Red patches of skin on your face, and tiny visible blood vessels and spots – these can be quite common symptoms. They may be caused by rosacea, a common facial skin inflammation.Skin diseases can be difficult to cope with, and they often affect people’s self-confidence and wellbeing. But if you have rosacea, there is a lot you can do on your own.

Wikipedia : 77 Rosacea is a long-term skin condition that typically affects the face. It results in redness, pimples,... more...

Related Diseases for Rosacea

Diseases related to Rosacea via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 323)
# Related Disease Score Top Affiliating Genes
1 contact dermatitis 30.3 CXCL8 IL6 TNF
2 pyoderma 30.2 CXCL8 MMP9 TNF
3 dermatitis, atopic 30.2 CAMP CXCL8 TNF
4 colitis 30.2 CXCL8 IL6 TNF
5 ulcerative colitis 30.0 CXCL8 IL6 TNF
6 keratitis, hereditary 29.9 MMP9 TLR2 VEGFA
7 inflammatory bowel disease 29.9 CXCL8 IL6 TLR2 TNF
8 fungal keratitis 29.8 MMP8 MMP9 TLR2
9 scabies 29.6 CXCL8 GSTM1
10 chlamydia 29.3 CXCL8 IL6 TLR2 TNF
11 arthritis 29.0 CXCL8 IL6 MMP3 MMP9 TNF
12 vascular disease 28.8 IL6 MMP3 MMP9 TNF VEGFA
13 rheumatoid arthritis 28.2 CXCL8 IL6 MMP3 MMP9 TLR2 TNF
14 granulomatous rosacea 12.7
15 rosacea conjunctivitis 12.1
16 dermatitis 10.6
17 neurofibromatosis, type ii 10.6
18 x-linked intellectual disability-macrocephaly-macroorchidism syndrome 10.5
19 radiation proctitis 10.4 TNF VEGFA
20 retinal dystrophy, iris coloboma, and comedogenic acne syndrome 10.4
21 periapical granuloma 10.4 CXCL8 MMP8
22 mycobacterium chelonae 10.3 CXCL8 TLR2
23 demodicidosis 10.3
24 penicilliosis 10.3 TLR2 TNF
25 congenital cytomegalovirus 10.3 TLR2 TNF
26 nontuberculous mycobacterial lung disease 10.3 TLR2 TNF
27 blood group, globoside system 10.3 IL6 VEGFA
28 angiokeratoma circumscriptum 10.3 MMP9 VEGFA
29 crohn's colitis 10.3 CXCL8 TNF
30 mycobacterium kansasii 10.3 CXCL8 TLR2
31 capillary leak syndrome 10.3 CXCL8 IL6
32 acute monoblastic leukemia 10.3 CXCL8 IL6
33 psoriasis 10.3
34 vibratory urticaria 10.3 CXCL8 MMP9
35 neurosyphilis 10.3 CXCL8 TLR2
36 exudative glomerulonephritis 10.3 CXCL8 TNF
37 amaurosis fugax 10.3 MMP8 MMP9
38 trench fever 10.3 TLR2 TNF
39 kashin-beck disease 10.2 TNF VEGFA
40 mycobacterium marinum 10.2 CAMP CXCL8 TLR2
41 autoimmune inner ear disease 10.2 MMP9 TNF
42 sick building syndrome 10.2 MMP9 VEGFA
43 tungiasis 10.2 CXCL8 TNF
44 adult dermatomyositis 10.2 TNF VDR
45 acute vascular insufficiency of intestine 10.2 IL6 TNF
46 osteosclerotic myeloma 10.2 IL6 TNF
47 posterior urethral valves 10.2 IL6 TNF
48 adult astrocytic tumour 10.2 MMP3 MMP9
49 recurrent corneal erosion 10.2 CXCL8 IL6
50 adamantinous craniopharyngioma 10.2 MMP9 VEGFA

Graphical network of the top 20 diseases related to Rosacea:



Diseases related to Rosacea

Symptoms & Phenotypes for Rosacea

UMLS symptoms related to Rosacea:


pruritus, exanthema

MGI Mouse Phenotypes related to Rosacea:

47 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.13 GTF2IRD1 IL6 MMP3 MMP8 MMP9 PTGDR
2 hematopoietic system MP:0005397 10.11 CAMP IL6 MMP3 MMP9 PTGDR TLR2
3 cardiovascular system MP:0005385 10.1 GTF2IRD1 IL6 MMP9 PTGDR TLR2 TNF
4 immune system MP:0005387 10.1 CAMP IL6 MMP3 MMP8 MMP9 PTGDR
5 integument MP:0010771 9.97 GTF2IRD1 IL6 MMP9 PTGDR TLR2 TNF
6 digestive/alimentary MP:0005381 9.95 IL6 MMP9 TLR2 TNF VDR VEGFA
7 muscle MP:0005369 9.92 GTF2IRD1 IL6 MMP9 PTGDR TLR2 TNF
8 nervous system MP:0003631 9.81 GTF2IRD1 IL6 MMP3 MMP9 PTGDR TLR2
9 neoplasm MP:0002006 9.8 GTF2IRD1 IL6 MMP8 MMP9 TLR2 TNF
10 respiratory system MP:0005388 9.5 GTF2IRD1 IL6 MMP9 PTGDR TLR2 TNF
11 skeleton MP:0005390 9.23 GTF2IRD1 IL6 MMP3 MMP9 TLR2 TNF

Drugs & Therapeutics for Rosacea

PubMedHealth treatment related to Rosacea: 64

There are a lot of creams, lotions and gels recommended for the treatment of rosacea. Creams and gels with either azelaic acid or the antibiotic metronidazole in them are used most commonly. Antibiotics can also be taken as tablets, but then the entire body is affected.

Drugs for Rosacea (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 164)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ivermectin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 70288-86-7 6474909
2
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 564-25-0 54671203
3
Azelaic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 123-99-9 2266
4
Metronidazole Approved Phase 4,Phase 3,Phase 2,Phase 1 443-48-1 4173
5
Ephedrine Approved Phase 4,Phase 3 299-42-3 9294
6
Phenylephrine Approved Phase 4,Phase 3 59-42-7 6041
7
Oxymetazoline Approved, Investigational Phase 4,Phase 3 1491-59-4 4636
8
Pseudoephedrine Approved Phase 4,Phase 3 90-82-4 7028
9
Sulfacetamide Approved Phase 4 144-80-9 5320
10
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2 22916-47-8 4189
11
Aminolevulinic acid Approved Phase 4,Not Applicable 106-60-5 137
12
Timolol Approved Phase 4,Phase 1 26839-75-8 33624 5478
13 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Anti-Inflammatory Agents Phase 4,Phase 2,Not Applicable
15 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
17 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
19 Autonomic Agents Phase 4,Phase 3,Not Applicable
20 Respiratory System Agents Phase 4,Phase 3,Phase 1,Phase 2
21 Pharmaceutical Solutions Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1
22 Antimalarials Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
23 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
24 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Brimonidine Tartrate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 70359-46-5
30 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Mydriatics Phase 4,Phase 3
32 Vasoconstrictor Agents Phase 4,Phase 3,Not Applicable
33 Nasal Decongestants Phase 4,Phase 3
34 Sympathomimetics Phase 4,Phase 3
35 Cardiotonic Agents Phase 4,Phase 3
36 Protective Agents Phase 4,Phase 3
37 Antirheumatic Agents Phase 4,Phase 2,Phase 1
38 Calcineurin Inhibitors Phase 4,Phase 2
39 Cyclosporins Phase 4
40 Antifungal Agents Phase 4,Phase 2
41 Immunologic Factors Phase 4,Phase 2,Phase 1
42 Immunosuppressive Agents Phase 4,Phase 2
43 Photosensitizing Agents Phase 4,Not Applicable
44 Anti-Arrhythmia Agents Phase 4,Phase 1
45 Adrenergic beta-Antagonists Phase 4,Phase 1
46 Adrenergic Antagonists Phase 4,Phase 1
47
Minocycline Approved, Investigational Phase 3,Phase 2,Phase 1 10118-90-8 5281021
48
Clindamycin Approved, Vet_approved Phase 2, Phase 3 18323-44-9 29029
49
Isotretinoin Approved Phase 3 4759-48-2 5538 5282379
50
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337

Interventional clinical trials:

(show top 50) (show all 167)
# Name Status NCT ID Phase Drugs
1 Intense Pulsed Light as an Adjunctive to Bromonidine for the Treatment of Rosacea Unknown status NCT03053700 Phase 4 Bromonide 0.33% gel
2 Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea Completed NCT01872715 Phase 4 Oracea
3 Internet Surveys and Their Impact on Adherence for Rosacea Completed NCT03048058 Phase 4 brimonidine topical gel 0.33% & survey;brimonidine topical gel 0.33% & SOC
4 MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea. Completed NCT02616250 Phase 4 Brimonidine 0.33% gel (Br);Ivermectin 1% cream (IVM)
5 Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo Completed NCT01308619 Phase 4 Doxycycline
6 Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea Completed NCT00855595 Phase 4 Azelaic acid (Finacea, BAY39-6251);Metronidazole (Metrogel);Doxycycline (Oracea)
7 Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study Completed NCT02147691 Phase 4 Azelaic acid 15%;Brimonidine 0.33%
8 Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea Completed NCT03380390 Phase 4 Oxymetazoline HCL 1.0% Cream
9 Safety and Efficacy Study to Compare Two Rosacea Treatment Regimens Completed NCT00495313 Phase 4 doxycycline;doxycycline
10 ORCA - Oracea® for Rosacea: A Community-based Assessment Completed NCT00892281 Phase 4 doxycycline (Oracea®) 40 mg modified release as monotherapy;doxycycline (Oracea®) 40 mg modified release as add-on therapy
11 Efficacy of Topical Cyclosporin for Ocular Rosacea Completed NCT00348335 Phase 4 Cyclosporine 0.05%;Ocular lubricant
12 A Multicenter Trial of a Topical Medication for Papulopustular Rosacea Applied Twice Daily Versus Once Daily Completed NCT00417937 Phase 4 azelaic acid 15% gel;azelaic acid 15% gel
13 Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo Completed NCT01426269 Phase 4 Doxycycline;Metronidazole;Placebo
14 Mirvaso in Use Study Completed NCT02249065 Phase 4 Brimonidine
15 Assess the Ability of MetroGel 1% to Deliver Moisture to Facial Skin After a Single Application Completed NCT00436527 Phase 4 Metronidazole gel 1%
16 Topical Brimonidine to Reduce Inflammation After IPL-treatment in Patients With Facial Telangiectasias Completed NCT02761174 Phase 4 Brimonidine
17 Azelaic Acid Foam 15% in the Treatment of Papulopustular Rosacea Recruiting NCT03418610 Phase 4 Azelaic Acid foam 15%
18 Photodynamic Therapy for Papulopustular Rosacea Recruiting NCT02075671 Phase 4 Aminolevulinic acid topical solution 20%
19 Oracea Soolantra Association in Patients With Severe Rosacea Active, not recruiting NCT03075891 Phase 4 Ivermectin 1% cream;Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules
20 Topical Timolol for the Treatment of Benign Vascular Periocular Lesions Withdrawn NCT01250457 Phase 4 topical Timolol
21 Topical 0.5% Ivermectin Cream for Treatment of Demodicidosis Unknown status NCT02036229 Phase 3 ivermectin cream 0.5%
22 Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea Completed NCT01318733 Phase 3 CD07805/47 gel 0.5%
23 Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea Completed NCT01555463 Phase 3 Azelaic acid foam, 15% (BAY39-6251);Vehicle foam
24 Azelaic Acid on Demodex Counts in Rosacea Completed NCT03035955 Phase 2, Phase 3 Azelaic acid
25 Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea Completed NCT02289352 Phase 3 Brimonidine;placebo
26 Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea Completed NCT01355458 Phase 3 CD07805/47 gel;Placebo
27 Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea Completed NCT01355471 Phase 3 CD07805/47 Gel;Placebo
28 A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea Completed NCT02393937 Phase 3 Reference: Metronidazole Gel 1%;Test: Metronidazole Gel 1%;Placebo Gel
29 A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea Completed NCT02120924 Phase 3 Azelaic acid
30 A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Patients With Rosacea Completed NCT03287791 Phase 3 Azelaic acid (Finacea®) Foam;Generic Azelaic Acid Foam;Vehicle Foam
31 Phase 3 Papulopustular Rosacea Study Completed NCT01494467 Phase 3 CD5024;Azelaic acid 15% Gel
32 Phase 3 Papulopustular Rosacea Study Completed NCT01493687 Phase 3 CD5024;Azelaic acid 15% Gel
33 A Study to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea Completed NCT03142451 Phase 3 FMX-103
34 Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea Completed NCT02132117 Phase 3 Oxymetazoline HCL Cream 1.0%;Vehicle to Oxymetazoline HCL Cream
35 Determine the Effect of Administering Periostat(R) Twice Daily on Patients With Acne Rosacea Completed NCT00041977 Phase 3 doxycycline hyclate 20 mg twice daily
36 Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea Completed NCT00823901 Phase 2, Phase 3 Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel;Placebo gel
37 A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea Completed NCT02095158 Phase 3 Oxymetazoline HCL Cream 1.0%
38 An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea Completed NCT03352323 Phase 3 Oxymetazoline
39 Isotretinoin in Papular-Pustular Rosacea Completed NCT00882531 Phase 3 isotretinoin;placebo
40 CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study Completed NCT01493947 Phase 3 Ivermectin 1% cream;Metronidazole 0.75% cream
41 Study of 0444 Gel in the Treatment of Inflammatory Lesions of Rosacea Completed NCT01016782 Phase 3 0444
42 Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea Completed NCT01659853 Phase 3 CD07805/47 gel 0.5%/CD07805/47 Vehicle;azelaic acid gel 15%
43 A Clinical Trial to Determine the Effects of 40 Mg Doxycycline Versus a Placebo Control for the Treatment of Rosacea Completed NCT00126399 Phase 3 doxycycline
44 Clinical Endpoint Study of Ivermectin 1% Cream Completed NCT02840461 Phase 3 Ivermectin Cream, 1%;Placebo/Vehicle cream
45 Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea Completed NCT02131636 Phase 3 AGN-199201;Vehicle to AGN-199201
46 Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face Completed NCT02800148 Phase 3 Azelaic acid foam;Azelaic acid foam;Azelaic acid foam - Placebo
47 Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea Completed NCT02795117 Phase 3 Ivermectin;Ivermectin (reference);Placebo
48 Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema of Rosacea Completed NCT01789775 Phase 3 Drug: CD07805/47 gel;CD07805/47 gel Placebo
49 Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea Completed NCT02385240 Phase 3 Brimonidine Topical Gel, 0.33 percent (Perrigo);Brimonidine Topical Gel, 0.33 percent (Reference);Placebo gel
50 Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel Completed NCT02576847 Phase 3 Omiganan

Search NIH Clinical Center for Rosacea

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: rosacea

Genetic Tests for Rosacea

Anatomical Context for Rosacea

MalaCards organs/tissues related to Rosacea:

42
Skin, Eye, Testes, Heart, Small Intestine, Pituitary, B Cells

Publications for Rosacea

Articles related to Rosacea:

(show top 50) (show all 1611)
# Title Authors Year
1
Treatment of granulomatous rosacea with chromophore gel-assisted phototherapy. ( 30854732 )
2019
2
Rosacea fulminans - coincidence of the disease with inflammatory bowel disease. ( 30801824 )
2019
3
Rosacea and Demodicosis: Little-known Diagnostic Signs and Symptoms. ( 30226528 )
2019
4
Risk of psychiatric disorders in rosacea: A nationwide, population-based, cohort study in Taiwan. ( 30466187 )
2019
5
Nickel Sensitivity In Rosacea Patients: A Prospective Case Control Study. ( 30621570 )
2019
6
Clinical effectiveness of novel rosacea therapies. ( 30639950 )
2019
7
Exploring the potential for rosacea therapeutics of siRNA dispersion in topical emulsions. ( 30650201 )
2019
8
Rosacea: Relative risk vs Absolute Risk of Malignant Comorbidities. ( 30654083 )
2019
9
Relationship between rosacea and dietary factors: A multicenter retrospective case-control survey. ( 30656725 )
2019
10
Clinical and erythema-Directed imaging evaluation of Papulo-Pustular rosacea with topical ivermectin: A 32 weeks duration study. ( 30663445 )
2019
11
Nuclear Factor Kappa-B is Enriched in Eyelid Specimens of Rosacea: Implications for Pathogenesis and Therapy. ( 30703356 )
2019
12
The mental health burden in acne vulgaris and rosacea: an analysis of the US National Inpatient Sample. ( 30706514 )
2019
13
Claudin reduction may relate to an impaired skin barrier in rosacea. ( 30714633 )
2019
14
Noninvasive assessment of subclinical atherosclerosis in patients with rosacea. ( 30717569 )
2019
15
Metronidazole loaded nanostructured lipid carriers to improve skin deposition and retention in the treatment of rosacea. ( 30727789 )
2019
16
Assessment of Skin Physiology Change and Safety After Intradermal Injections With Botulinum Toxin: A Randomized, Double-Blind, Placebo-Controlled, Split-Face Pilot Study in Rosacea Patients With Facial Erythema. ( 30730346 )
2019
17
A Decade Retrospective Study of Light/Laser Devices in Treating Nasal Rosacea. ( 30732485 )
2019
18
Natural Skin Care Products as Adjunctive to Prescription Therapy in Moderate to Severe Rosacea ( 30794364 )
2019
19
Erythematotelangiectatic rosacea may be associated with a subclinical stage of demodicosis. A case control study. ( 30801673 )
2019
20
Unusual case of rosacea fulminans after topical metronidazole application. ( 30801678 )
2019
21
A novel moisturizer with high sun protection factor improves cutaneous barrier function and the visible appearance of rosacea-prone skin. ( 30803131 )
2019
22
Global rosacea treatment guidelines and expert consensus points: The differences. ( 30809947 )
2019
23
Spanish Consensus Document on the Treatment Algorithm for Rosacea. ( 30837074 )
2019
24
Characterization of the Blood Microbiota in Korean Females with Rosacea. ( 30844814 )
2019
25
Increased Risk of Cardiovascular Diseases in Female Rosacea Patients: A Nested Case-control Study. ( 30848290 )
2019
26
Rosácea infantil. ( 30907384 )
2019
27
Acne and Rosacea: Special Considerations in the Treatment of Patients With Latin American Ancestry ( 30909359 )
2019
28
It takes one to know one: exploring patient dialogue on rosacea web-based platforms and their potential for significant harm. ( 29676186 )
2019
29
Dose, duration, and cost: opportunities to improve use of long-term oral antibiotics for people with rosacea. ( 29676194 )
2019
30
Successful treatment of erythematotelangiectatic rosacea with intense pulsed light: Report of 13 cases. ( 29952023 )
2018
31
Efficacy and Safety of Oxymetazoline Cream 1.0% for Treatment of Persistent Facial Erythema Associated With Rosacea: Findings From the 52-Week Open Label REVEAL Trial. ( 29409914 )
2018
32
In Vitro Safety Pharmacology Profiling of Topical I+-Adrenergic Agonist Treatments for Erythema of Rosacea. ( 29374829 )
2018
33
Rosacea-like demodicosis (but not primary demodicosis) and papulo pustular rosacea may beA two phenotypes of the same disease-a microbioma,therapeutic and diagnostic tools perspective. ( 29959784 )
2018
34
Frontal fibrosing alopecia and cutaneous comorbidities: A potential relationship with rosacea. ( 29447678 )
2018
35
A case report of granulomatous rosacea of the face. ( 29748691 )
2018
36
Social factors and aromatase gene expression during adult male-to-female sex change in captive leopard grouper Mycteroperca rosacea. ( 29357278 )
2018
37
Rosacea-like cutaneous localization of small lymphocytic lymphoma unmasked by high-frequency-ultrasound. ( 29790607 )
2018
38
Increased expression of IL-33 in rosacea skin and UVB-irradiated and LL-37-treated HaCaT cells. ( 29873850 )
2018
39
Efficacy and Safety of Topical Oxymetazoline Cream 1.0% for Treatment of Persistent Facial Erythema Associated With Rosacea: Findings From the Two Phase 3, 29-Day, Randomized, Controlled REVEAL Trials. ( 29409915 )
2018
40
Clinically Relevant Reduction in Persistent Facial Erythema of Rosacea on the First Day of Treatment With Oxymetazoline Cream 1.0. ( 29879249 )
2018
41
Topical Ivermectin in the Treatment of Papulopustular Rosacea: A Systematic Review of Evidence and Clinical Guideline Recommendations. ( 29943217 )
2018
42
Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the First REVEAL Trial. ( 29320594 )
2018
43
Rosacea and alcohol intake. ( 29126626 )
2018
44
To test or not to test: A study examining the return rates of rosacea patients treated with a pulsed dye laser. ( 29388860 )
2018
45
Dual-Frequency Ultrasound as a New Treatment Modality for Refractory Rosacea: A Retrospective Study. ( 29746429 )
2018
46
Patient Preferences and Therapeutic Satisfaction with Topical Agents for Rosacea: A Survey-Based Study. ( 29915642 )
2018
47
Fifteen Minute Test May Save 15% or More on Rosacea Treatment. ( 29879260 )
2018
48
IL-1I+ and MMP-9 Tear Levels of Patients with Active Ocular Rosacea before and after Treatment with Systemic Azithromycin or Doxycycline. ( 29874670 )
2018
49
Assessment of rosacea symptom severity by genome-wide association study and expression analysis highlights immuno-inflammatory and skin pigmentation genes. ( 29771307 )
2018
50
Prevalence of gastrointestinal comorbidities in rosacea: Comparison of subantimicrobial, modified release doxycycline versus conventional release doxycycline. ( 29332715 )
2018

Variations for Rosacea

Expression for Rosacea

Search GEO for disease gene expression data for Rosacea.

Pathways for Rosacea

Pathways related to Rosacea according to GeneCards Suite gene sharing:

(show all 46)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.93 CAMP CXCL8 IL6 MMP3 MMP8 MMP9
2
Show member pathways
13.27 CXCL8 IL6 MMP3 MMP9 TNF VEGFA
3
Show member pathways
13.1 CAMP CXCL8 IL6 TLR2 TNF
4
Show member pathways
12.86 CXCL8 IL6 MMP9 TLR2 TNF VEGFA
5 12.78 CXCL8 GSTM1 IL6 MMP9 VEGFA
6
Show member pathways
12.53 CXCL8 GTF2IRD1 IL6 TLR2 TNF
7 12.25 MMP9 TLR2 TNF VEGFA
8
Show member pathways
12.22 CXCL8 IL6 TLR2 TNF
9 12.2 CXCL8 IL6 MMP3 MMP9
10
Show member pathways
12.17 CXCL8 MMP3 MMP8 MMP9 TLR2
11
Show member pathways
12.16 CXCL8 IL6 TLR2 TNF
12
Show member pathways
12.12 CXCL8 IL6 TLR2 TNF
13 12.11 CXCL8 IL6 TNF VEGFA
14 12.11 CAMP IL6 TLR2 TNF VDR
15
Show member pathways
12.07 CXCL8 IL6 MMP3 MMP9 TLR2 TNF
16 12.02 GSTM1 MMP9 TNF VEGFA
17 12.02 IL6 MMP9 TLR2 TNF VEGFA
18
Show member pathways
11.98 IL6 TLR2 TNF
19 11.95 CXCL8 IL6 MMP9 TNF
20 11.9 IL6 MMP3 MMP9 TNF
21 11.85 CXCL8 IL6 TNF VEGFA
22
Show member pathways
11.83 MMP3 MMP8 MMP9 TNF
23
Show member pathways
11.82 IL6 MMP3 MMP9 TLR2 TNF
24 11.81 CXCL8 IL6 TLR2 TNF
25 11.73 CXCL8 IL6 TNF
26 11.71 CXCL8 MMP9 VEGFA
27 11.69 CXCL8 IL6 MMP3 MMP9 TNF VEGFA
28 11.65 CXCL8 IL6 MMP9
29 11.65 IL6 MMP3 MMP9 TNF
30 11.62 CXCL8 MMP3 MMP9
31 11.59 MMP9 PTGDR VEGFA
32 11.58 CXCL8 IL6 MMP9 TNF
33 11.53 CXCL8 IL6 VEGFA
34 11.5 CXCL8 IL6 TNF
35 11.48 IL6 MMP9 TNF
36 11.47 CXCL8 IL6 TLR2 TNF
37 11.45 IL6 TNF VDR
38 11.39 CXCL8 IL6 MMP3 TLR2 TNF VEGFA
39 11.36 CXCL8 IL6 TLR2 TNF
40 11.29 CXCL8 IL6 MMP9
41 11.08 MMP9 VEGFA
42 11.08 CXCL8 TNF
43 11.04 IL6 TNF
44 10.97 CXCL8 IL6 TNF
45
Show member pathways
10.9 CXCL8 IL6 MMP3 MMP9 TNF VEGFA
46 10.83 TNF VDR

GO Terms for Rosacea

Cellular components related to Rosacea according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.76 CAMP CXCL8 IL6 MMP3 MMP8 MMP9
2 extracellular matrix GO:0031012 9.56 MMP3 MMP8 MMP9 VEGFA
3 extracellular space GO:0005615 9.23 CAMP CXCL8 IL6 MMP3 MMP8 MMP9
4 tertiary granule lumen GO:1904724 9.13 CAMP MMP8 MMP9

Biological processes related to Rosacea according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.93 CXCL8 IL6 TNF VEGFA
2 negative regulation of cell proliferation GO:0008285 9.93 CXCL8 IL6 TLR2 VDR
3 inflammatory response GO:0006954 9.83 CXCL8 IL6 PTGDR TLR2 TNF
4 positive regulation of angiogenesis GO:0045766 9.8 CAMP CXCL8 VEGFA
5 cellular response to lipopolysaccharide GO:0071222 9.8 CAMP CXCL8 IL6 TNF
6 positive regulation of gene expression GO:0010628 9.8 IL6 MMP8 TLR2 TNF VDR VEGFA
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.79 IL6 TLR2 TNF
8 defense response GO:0006952 9.79 CAMP CXCL8 TNF
9 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.72 IL6 TNF VEGFA
10 defense response to Gram-positive bacterium GO:0050830 9.71 CAMP IL6 TLR2 TNF
11 extracellular matrix disassembly GO:0022617 9.7 MMP3 MMP8 MMP9
12 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.69 MMP8 TLR2 TNF
13 collagen catabolic process GO:0030574 9.63 MMP3 MMP8 MMP9
14 microglial cell activation GO:0001774 9.61 TLR2 TNF
15 embryonic digestive tract development GO:0048566 9.6 CXCL8 TNF
16 macrophage differentiation GO:0030225 9.59 MMP9 VEGFA
17 positive regulation of glial cell proliferation GO:0060252 9.58 IL6 TNF
18 negative regulation of growth of symbiont in host GO:0044130 9.58 CAMP TNF
19 induction of positive chemotaxis GO:0050930 9.57 CXCL8 VEGFA
20 response to molecule of bacterial origin GO:0002237 9.56 CXCL8 TLR2
21 positive regulation of interleukin-6 production GO:0032755 9.56 IL6 MMP8 TLR2 TNF
22 negative regulation of lipid storage GO:0010888 9.54 IL6 TNF
23 positive regulation of chemokine production GO:0032722 9.54 IL6 TLR2 TNF
24 regulation of microglial cell activation GO:1903978 9.48 MMP8 TNF
25 cytokine-mediated signaling pathway GO:0019221 9.43 CXCL8 IL6 MMP3 MMP9 TNF VEGFA
26 positive regulation of neuroinflammatory response GO:0150078 9.33 IL6 MMP8 TNF
27 regulation of neuroinflammatory response GO:0150077 8.8 MMP3 MMP8 MMP9

Molecular functions related to Rosacea according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 metalloendopeptidase activity GO:0004222 9.33 MMP3 MMP8 MMP9
2 endopeptidase activity GO:0004175 9.13 MMP3 MMP8 MMP9
3 cytokine activity GO:0005125 8.92 CXCL8 IL6 TNF VEGFA

Sources for Rosacea

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....